¿Importa la secuencia de tratamiento en egfr +?: Factores que deberían ser considerados

32 / 33

• No doubt FLAURA is a positive trial
• Comparing to 2 nd generation TKIs
– Subgroup of EGFR mutation positive patients may attain long duration
of PFS
– Better toxicity profile with 2 nd generation TKIs
• CNS met
– Sufficient evident supporting first line osimertinib for patients with CNS
met at presentation
• Optimal sequencing for OS
– Remain unclear, and pending on final OS data from AURA 3 and
FLAURA
TAKE HOME MESSAGES